Around 2,000 people in Guwahati and around 26,000 people in India are likely to be administered doses of Covaxin, as part of the Phase III clinical trial of India’s first COVID-19 vaccine candidate.
Though the date for commencement of human trials in Guwahati is yet to be finalized, it is likely to begin by the end of this month or early next month.
suggest that the trial would take about a month’s time, or may be even more.
It may be mentioned that Guwahati initially was picked as a centre for the Phase II trials, but later it was decided that it will be one of the centres in the Phase III trials.
Covaxin – BBV152 coronavirus vaccine – is one of the frontrunners in the race for a COVID-19 vaccine in India. It is being developed by Bharat Biotech in collaboration with researchers from the ICMR’s National Institute of Virology.